Introduction: The efficacy and safety of
INTRODUCTION
Despite the number of antidiabetes medications currently available, there is still difficulty achieving tight glycemic control in patients with type 2 diabetes [1] . An emerging class of antidiabetes agents, known as incretin-based therapies, enhances or replaces the glucosedependent glucoregulatory effects of incretin hormones, primarily glucagon-like peptide-1 (GLP-1) [2] . Native GLP-1 regulates the postprandial rise in blood glucose by augmenting insulin release and blunting glucagon secretion, delaying gastric emptying, and improving satiety. These effects are shortlived, as the active hormone is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4).
To take advantage of the incretin system, two types of incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) have been developed and have been shown to improve fasting and postprandial glucose control with minimal hypoglycemia, and to induce weight loss to varying extents based on their relative stimulation of incretin activity [3, 4] . Currently, there are two GLP-1 receptor agonists (liraglutide and exenatide) available for treating type 2 diabetes. Liraglutide, administered as a once-daily (QD) injection, has demonstrated to be effective in improving glycemic control, with a lower risk of hypoglycemia, and appreciable weight loss [5, 6] . Exenatide, available for administration as a twice-daily injection and in some countries as a once-weekly (QW) injection, results in improved glycemic control, without hypoglycemia, and significant weight loss [7, 8] . The most common treatment-emergent adverse events (AEs) observed with GLP-1 receptor agonists are related to gastrointestinal AEs (nausea, vomiting, diarrhea, and upper abdominal pain). These AEs are considered dose-related and typically become less frequent with subsequent dosing over time.
Several DPP-4 inhibitors are approved, including sitagliptin, saxagliptin, and linagliptin. These QD agents have the advantage of being oral medications, but offer modest glycemic efficacy and have little effect on body weight [9] [10] [11] .
Taspoglutide, a human GLP-1 analog, elicits a long-lasting incretin effect through its enhanced enzymatic stability and sustained-release formulation, allowing for QW administration [12] . In phase 2 trials, taspoglutide QW versus placebo in combination with metformin favorably lowered blood glucose and body weight, and was well tolerated [13, 14] . The present study (T-emerge 4) was designed to compare the efficacy and safety of taspoglutide versus sitagliptin or placebo over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin alone. A short-term extension phase of 28 weeks followed by a longterm extension phase of 52 weeks were planned to follow the core phase of the study to evaluate long-term effects of taspoglutide compared with sitagliptin. The trial was terminated on January 11, 2011 during the long-term extension phase owing to the discontinuation of dosing in the phase 3 trials because of higher than expected rates of study withdrawals of taspoglutidetreated patients. Here, the authors present key efficacy results from the 24-week core phase and 28-week short-term extension phase, and full safety data for the entire study up to the last dose administered.
MATERIALS AND METHODS

Study Design and Interventions
This phase 3 study was a randomized, The trial was conducted in accordance with the Declaration of Helsinki and national regulations, and the protocol was approved by local independent ethics committees or institutional review boards. All participants provided written consent prior to any procedure.
Randomization and Masking
Randomization was stratified by baseline HbA 1c (\8.0% or C8.0%) to prevent imbalances in the treatment arms. Randomization was performed centrally using either a telephone-or web-based system, and patient randomization numbers were generated by the sponsor. Investigators were masked to the results of efficacy assessments during the study, and the sponsor medical review of data avoided systematic unblinding of the treatment code.
Study Endpoints
The 
RESULTS
Overall, 666 patients were randomized and 656 (98%) qualified for the safety population (i.e., received at least one dose of study medication and had at least one safety assessment). Of those randomized, 542 (81%) patients completed the 24-week core phase and 437 (66%) patients completed the 28-week short-term extension phase (Fig. 2) . During the core phase, premature discontinuation occurred in 21%, 28%, 7%, and 11% of patients receiving taspoglutide 10 mg, taspoglutide 20 mg, sitagliptin 100 mg, or placebo, respectively, most frequently resulting from AEs. Across the core phase and short-term At 24 weeks, both doses of taspoglutide achieved significantly greater reductions in fasting plasma glucose than sitagliptin or placebo (Fig. 4a) . The mean reductions from baseline in fasting plasma glucose were -2.16 mmol/L (SE 0.14), -2.34 mmol/L (SE 0.14), -1.35 mmol/L (SE 0.14), and -0.07 mmol/L (SE 0.20) for taspoglutide 10 mg, taspoglutide 20 mg, sitagliptin 100 mg, (8) 14 (7) 19 (11) Black 5 (6) 13 (7) 8 (4) 10 (6) Other 7 (8) 11 (6) 12 (6) 13 (7) Ethnicity Tables 4 and 5 in the Appendix.
Safety and Tolerability
A majority of patients receiving taspoglutide or sitagliptin experienced at least one AE during the entire study period with most being reported as mild-to-moderate in intensity ( Withdrawals resulting from AEs were more common among patients receiving taspoglutide compared with sitagliptin. In the taspoglutide groups, the most common AEs leading to withdrawal were nausea, vomiting, hypersensitivity, and injection-site-related AEs.
In the taspoglutide groups, 18.2-20.3% of patients withdrew because of gastrointestinal AEs compared with 1.6% of those in the These results are consistent with other studies of incretin-based therapies in similar populations failing to achieve glycemic control with metformin. In comparative studies, liraglutide QD and exenatide QW achieved greater glycemic efficacy than sitagliptin. Liraglutide achieved HbA 1c reductions of -1.24% to -1.50% versus -0.90% with sitagliptin, while exenatide QW achieved -1.5% versus -0.9% [8, 15] . In other phase 3 trials, GLP-1 receptor agonists have achieved generally comparable HbA 1c reductions, although some variability in the treatment responses may have been due to differences in background therapies and baseline HbA 1c [5, 6, 8, [15] [16] [17] [18] . The efficacy of sitagliptin in recent comparative trials, including the present study, was similar to previous studies with HbA 1c improvements of -0.67% to -1.0%
in metformin-treated patients [9, 10] .
Previous studies have also demonstrated greater effects on weight loss with GLP-1 receptor agonists when compared with liraglutide, respectively, versus 0.96 kg for sitagliptin [15] . Exenatide QW achieved a weight loss of 2.3 kg compared with 0.8 kg for sitagliptin [8] . In other studies, sitagliptin has demonstrated only minimal reductions in body weight of 0.5-0.7 kg [9, 10] . In general, the overall safety profile of taspoglutide was notably worse than sitagliptin primarily because of gastrointestinal events, systemic allergic reactions, and injection-site reactions. However, there was a higher incidence of nasopharyngitis and upper respiratory tract infections reported with sitagliptin than with taspoglutide. The incidence of overall AEs was higher in the taspoglutide 10 mg (85.6%) and taspoglutide 20 mg (95.3%) groups than in the sitagliptin (81.0%) group. The
AEs leading to withdrawal were approximately four-to-five-times higher in the taspoglutide 10 mg (27.8%) and taspoglutide 20 mg (35.9%) groups than in the sitagliptin (7.1%) group.
The greater frequency of gastrointestinal events, primarily nausea, vomiting, and dyspepsia, observed in patients treated with taspoglutide is consistent with that of other GLP-1 receptor agonists [5, 6, 8, [15] [16] [17] [18] . In this study, although the gastrointestinal events were usually mild-to-moderate, 19.3% of patients in the taspoglutide groups experienced gastrointestinal events that led to withdrawals during the course of the study.
Although systemic allergic reactions to protein-based therapies do occur, the incidence observed with taspoglutide treatment is notably higher than what has been reported with other GLP-1 receptor agonists [19] . The most frequent allergic reactions to occur were hypersensitivity. As a result of the risk mitigation plan implemented during the long-term extension phase of the study, patients with a systemic allergic reaction were discontinued from the study. agonists, exenatide and liraglutide [19] . Antibody formation to the respective GLP-1 receptor agonist has been reported in 32% and 45% of patients treated with exenatide twice-daily and exenatide QW, respectively [20] , and 4-13% of patients treated with liraglutide q.d [21, 22] .
Taspoglutide was associated with high rates of injection-site events, such as erythema, pruritus, and nodules. In two exenatide studies, injectionsite reactions, such as bruising were rarely reported [7, 23] .
In the present study, hypoglycemia was a rare occurrence and the number of events was generally comparable between taspoglutide and sitagliptin groups. Similar low rates of hypoglycemia have been observed for the other GLP-receptor agonists, exenatide and liraglutide [5, 6, [16] [17] [18] . This study provides long-term follow-up beyond the standard 24-week endpoint; however, longer-term evaluations outside of the clinical trial setting are needed to determine durability of the response and clinical benefit in this highly prevalent, chronic disease. 1 In September 2010, Roche decided to stop dosing patients in the taspoglutide phase III trials because higher than expected discontinuation rates of taspoglutide-treated patients were observed, mainly due to gastrointestinal intolerability, and as a result of the implementation of the risk-mitigation plan to address serious hypersensitivity reactions. Since this time, Roche has worked on the root cause analysis and on the modified taspoglutide formulations with the input of Ipsen. After further analysis, Roche has now made the decision to stop the development of taspoglutide and to return the product to the originator, Ipsen, which is currently pursuing further investigations.
Limitations of this study should be considered when extrapolating the findings to a population beyond those in this study, such as participants with relatively new-onset diabetes, monotherapy limited to metformin, and majority of participants being non-Hispanic whites. In addition, although patients were advised to maintain pre-study diet and exercise habits, there was a lack of rigor with standardization of patients' diet and exercise regimens during the study, which could have compromised the true weight loss potential of taspoglutide.
In conclusion, the current findings showed that taspoglutide QW has several key advantages over sitagliptin, as adjunct to metformin, including superior glycemic control and increased weight loss without increased risk of hypoglycemia. However, treatment with taspoglutide was associated with substantial rates of gastrointestinal intolerability and allergic reactions, and led to high subsequent rates of discontinuation.
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